首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Current Cancer Drug Targets

Current Cancer Drug Targets杂志,由Bentham Science Publishers B.V.出版,于2001年创刊,Bimonthly,出版语言English,ISSN:1568-0096,E-ISSN:1873-5576。

投稿咨询
Current Cancer Drug Targets
Current Cancer Drug Targets
Current Cancer Drug Targets
SCI SCIE

杂志介绍

JCR分区
Q3
中科院分区
3区
影响因子
2.5
CiteScore
4.2
期刊收录
SCI、SCIE

Current Cancer Drug Targets(中文译名:《当前的抗癌药物靶点》),ISSN:1568-0096,EISSN:1873-5576,是Bentham Science Publishers B.V.出版的国际性学术期刊,创刊于2001年,以Bimonthly形式稳定发行,2026年总发文量约132篇。该刊采用非OA开放访问,学科归属为医学 - 肿瘤学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达2.5,2025年期刊CiteScore为4.2,2025年期刊自引率约0%,在中科院期刊分区体系中位列医学大类3区,在所属学科领域具备高学术影响力与国际认可度。Current Cancer Drug Targets长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期约1月,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,CHINA MAINLANDUSA、India、Italy、Iran、England、Japan等为核心发文国家与地区;IRCCS FONDAZIONE PASCALESUN YAT SEN UNIVERSITY、FUZHOU UNIVERSITY、IRCCS AVIANO (CRO)、NATL CANC INST、STATE KEY LAB ONCOLOGY SOUTH CHINA、UNIVERSITY OF TEXAS SYSTEM等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
ONCOLOGY 肿瘤学
4区
否 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
ONCOLOGY 肿瘤学
4区
否 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
ONCOLOGY 肿瘤学
4区
否 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q3 204 / 333

38.9

学科:ONCOLOGY SCIE Q3 224 / 333

32.88

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 106 / 328

67.8

学科:ONCOLOGY SCIE Q3 202 / 328

38.57


中国学者近期发文

1
Exploration of the Synergistic Effect of Chitosan Oligosaccharide and Dacarbazine (DTIC) in the Treatment of Melanom

Author:Zhang, Xin; Chen, Wencui; Zhang, Keke; Liu, Zhende; Lyu, Qianqian; Jin, Liming; Liu, Weizhi

Journal: CURRENT CANCER DRUG TARGETS. 2026; Vol. , Issue , pp. -. DOI: 10.2174/0115680096423297251202110111

2
In Silico Multi-omics Analyses of Kinesin Family Member 15 in Pan-Cancer and Validation in Tissue Microarra

Author:Xiang, Mengqin; Hu, Qing; Li, Yanchun; Wu, Hao

Journal: CURRENT CANCER DRUG TARGETS. 2026; Vol. , Issue , pp. -. DOI: 10.2174/0115680096420482251130063549

3
Comparative Analysis of Homologous Recombination Repair Status Across Gynecologic and Breast Cancers in Chinese Population

Author:Huang, Yongsheng; Shao, Jiajia; Yin, Xinke; Jiang, Yuanling; Luo, Jiahuan; Huang, Jinghua; Zhao, Jianli; Fu, Sha; Liao, Jianwei

Journal: CURRENT CANCER DRUG TARGETS. 2026; Vol. , Issue , pp. -. DOI: 10.2174/0115680096437832251215093401

4
NDUFA10: An Emerging Oncogenic Driver of Metastasis in Lung Adenocarcinom

Author:Hu, Tianqi; Chen, Yixin; Lu, Yi; He, Yuyu; Chou, Lunan; Fu, Jiali; Huang, Kate; Wang, Yumin; Chen, Jie

Journal: CURRENT CANCER DRUG TARGETS. 2026; Vol. , Issue , pp. -. DOI: 10.2174/0115680096440556260123113410

5
A Novel Oncogene and Therapeutic Target, Germ Cell-Specific Gene 2 (GSG2), Plays Complex Roles in Promoting Malignant Progression of Gliom

Author:Niu, Zihui; Hou, Shiqiang; Sun, Zhiming; Wang, Zihao; Wang, Jing; Wang, Chao; Zhang, Kang; Wang, Jiajun; Zhang, Chao; Shi, Xingjie; Lin, Ning; Zhang, Lanlan

Journal: CURRENT CANCER DRUG TARGETS. 2026; Vol. , Issue , pp. -. DOI: 10.2174/0115680096460851260218062401

6
Methyl-β-Cyclodextrin Enhances the Chemotherapeutic Efficacy of Paclitaxel in Breast Cancer Cell

Author:Jin, Haili; Zhou, Liping; Lin, Tianzhen; Chen, Wenbin; Yang, Ruhui

Journal: CURRENT CANCER DRUG TARGETS. 2026; Vol. , Issue , pp. -. DOI: 10.2174/0115680096430730260120060026

7
Immunotherapy with Chemotherapy in Recurrent or Metastatic Maxillary Sinus Squamous Cell Carcinoma: A Real-world Study in Chin

Author:Zhang, Shuyang; Zhao, Jingyang; Shi, Yijun; Zhu, Changyu; Li, Xinyu; Zhang, Weitao; Liu, Heshu; Li, Wei

Journal: CURRENT CANCER DRUG TARGETS. 2026; Vol. , Issue , pp. -. DOI: 10.2174/0115680096443625260219081015

8
MiR-124-3p Suppresses Glioma Cells Progression by Targeting STAT3/NAMPT and Inhibiting AKT/ERK Signalin

Author:Liu, Yan; Zhao, Wei; Tang, Zhi; Liu, Wenwu; Wang, Lei; Wang, Te

Journal: CURRENT CANCER DRUG TARGETS. 2026; Vol. , Issue , pp. -. DOI: 10.2174/0115680096444128260128052644

9
Clinical Application of PARP1 Inhibitors and Challenges in Cancer Therap

Author:Luo, Yunlin; Nie, Mingcheng; Chen, Yuekang; Huang, Xinyu; Cui, Xuehai; Lin, Wan; Xu, Liyan; Li, Enmin; Cheng, Yinwei

Journal: CURRENT CANCER DRUG TARGETS. 2026; Vol. 26, Issue 1, pp. 1-35. DOI: 10.2174/0115680096327635241021115944

10
A Novel Platinum-Resistance-related Gene Signature in Ovarian Cancer: Identification and Patient-derived Organoids Verificatio

Author:Lin, Jie; Cai, Xintong; Liu, Linying; Li, Anyang; Huang, Huaqing; Fu, Yixin; Dai, Zhisen; Sun, Yang

Journal: CURRENT CANCER DRUG TARGETS. 2026; Vol. 26, Issue 1, pp. 64-84. DOI: 10.2174/0115680096326784241009113454


在线咨询

Current Cancer Drug Targets

国际简称:CURR CANCER DRUG TAR参考译名:当前的抗癌药物靶点

年发文量:132 CiteScore:4.2 是否预警:否 Gold OA文章占比:8.03% 研究类文章占比:60.61%

杂志社联系方式:BENTHAM SCIENCE PUBL LTD, EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, SHARJAH, U ARAB EMIRATES, 1200 BR

Current Cancer Drug Targets